Eli Lilly and Company TodayLLYEli Lilly and Company$945.17 -7.57 (-0.79%) 52-Week Range$516.57▼$972.53Dividend Yield0.55%P/E Ratio139.20Price Target$956.88Add to WatchlistEli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stock is trading back near its all-time high at $972.52. Its market capitalization hovers around the $857 billion mark. The company has many growth ...

The drugmaker looks unstoppable.To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask Eli Lilly (LLY -0.15%), a pharmaceutical company that has been flying on all cylinders. The drugmaker continues to impress investors with exceptional financial results, impressive regulatory wins, and exciting clinical progress.Much of the company's recent success has to do with tirzepatide, a medicine for diabetes (marketed as Mounjaro) and for ob ...

The S&P 500's top three at year-end could look a little different than they do now.You've likely heard some form of the disclaimer, "Past performance is no guarantee of future results." And the statement is true. However, I'd add something to the disclaimer: "But a big head start is nearly always a good thing."Several large-cap stocks have a big head start that could enable them to finish the year strong. I predict these will be the three best-performing S&P 500 (^GSPC 1.15%) stocks of 2024.1. NvidiaNvidia ...

Core Viewpoint - Eli Lilly's current high valuation may be justified by its rapid earnings growth, particularly driven by its successful diabetes drug Mounjaro and its new weight-loss treatment Zepbound, which could become the company's top seller in the near future [1][2]. Financial Performance - For the three-month period ending June 30, Eli Lilly's revenue increased by 36% year over year to $11.3 billion, largely due to the growth of Mounjaro and Zepbound [2]. - The company's operating income rose by 75% to $3.7 billion, despite incurring asset impairment and restructuring charges totaling $435 million during the period [2]. - Net income climbed by 68% to just under $3 billion, indicating strong earnings growth that supports the company's high valuation of $830 billion [2]. Growth Potential - Eli Lilly's stock trades at over 100 times its trailing profit, but the expected high earnings growth rate may mitigate concerns about its valuation [3]. - The company is positioned for significant future growth, which could make the stock appear less expensive than it currently seems [3]. Profitability Metrics - Eli Lilly's gross profit margin was 81% last quarter, with revenue rising by 36% while the cost of sales increased by only 20%, indicating operational efficiency [4]. - Maintaining high gross profit margins can lead to substantial earnings growth, as incremental sales growth will largely contribute to the bottom line [4]. Investment Outlook - Eli Lilly is expected to continue experiencing high sales growth, supported by impressive gross profit margins, which enhances confidence in its ability to increase earnings rapidly [6]. - The company faces challenges in meeting soaring product demand but is well-positioned to invest in operations to strengthen its manufacturing capabilities [6]. - With strong growth prospects and high margins, Eli Lilly stock is considered an excellent long-term investment opportunity [6].

Shares of Eli Lilly (LLY) rose more than 3% on Tuesday after reporting long-term data from the late-stage SURMOUNT-1 study. Data from this study showed that treatment with tirzepatide over three years lowered the risk of developing type 2 diabetes (T2D) by 94% compared with placebo, in obese or overweight adults with pre-diabetes.A dual GIP and GLP-1 receptor agonist, tirzepatide is the active ingredient used in the company’s two blockbuster medications — obesity drug Zepbound and diabetes drug Mounjaro.The ...

Key TakeawaysEli Lilly shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company’s diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients. The stock has oscillated within a broadening wedge since early May last year, with an earnings-driven gap on Aug. 8 accelerating recent bullish momentum.Eli Lilly shares may encounter support around $885 and $790, but ru ...

The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.Shares of Eli Lilly (LLY 3.06%) have already soared by about 58% in 2024. Despite the run-up, many analysts on Wall Street think the pharmaceutical stock can climb a lot higher. Bank of America analyst Geoff Meacham is so encouraged by the company's recent progress with obesity, diabetes, and Alzheimer's disease that he thinks the stock can climb to $1,150 per share.Meacham's recently updated pric ...

Shares of Eli Lilly jumped Tuesday after a study showed its blockbuster weight-loss drug significantly reduced the risk of overweight patients developing type 2 diabetes. Results from a recent trial showed weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity compared to the placebo, according to the pharmaceutical giant. The treatment with the drug, currently sold under the brand names Zepbound and Mounjaro, ...

The company had very encouraging news to report about its hottest product.The U.S. pharmaceutical stock of the moment, Eli Lilly (LLY 3.06%), did rather well on Tuesday. Its price closed the day more than 3% higher, on the back of some good news from the lab about its hottest product. What also helped was a glowing new research note from an analyst. The stock's performance looked even better when matched against that of the S&P 500 index, which dipped by 0.2%.Zepbound for gloryThat hot product is obesity tr ...

Scott Olson/Getty Images News Eli Lilly and Company's (LLY) tirzepatide (Mounjaro/Zepbound) continues to produce commercial and clinical wins. After a stellar second quarter earnings report and a $3 billion revenue guidance raise, Eli Lilly announced positive topline results from the SURMOUNT-1 trial where tirzepatide reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity/overweight compared to placebo. These results once again show the significant benefits of the incr ...